page

Search

1 2 3230 231 232 233 234527
Showing 23112320 of 5261 Items
March 04, 2019

Advantis Corp. Prepares for OTCBB

Page
Newport Beach, CA - (NewMediaWire) - March 04, 2019 - ADVANTIS CORPORATION (OTC PINK: ADVT) announced today that it is preparing for the audit necessary for their OTCBB up-listing. Advantis is currently trading in the less regulated, more thinly traded OTC Pink Sheets.Advantis has been preparing for their fully-reporting status since 2017. The previous CEO set the initial target for the end of last year. The current CEO, Darren Cherry, says he delayed the up-listing so the company could be in a more solid financial position. “Our revenue continues to increase, we are establishing brand recognition, and have several opportunities to expand upon,” Cherry related. “This year our revenue will be well over a million, and several product launches are ahead. We’re ready.” Cherry says that up-listing will put Advantis in a more liquid exchange, and the more stringent reporting requirement will boost confidence that investors have in them. “This is the paramount step for our company. The step that will make so much more possible. There will be many more eyes on us with the opportunity to benefit from our continued growth,” Cherry asserted.The timing of the up-listing coincides with several product launches, Cherry explained, “Between now and the time we are a fully-reporting company we have the sublingual launch, the Pet Division… we’re looking at about four or five months until the process is completed and the form is filed. It will be real nice to have some additional revenue streams activated just as we become established on the OTC Big Board.” Cherry concluded his comments by saying that the legal and accounting arrangements are underway.Advantis wishes to thank Investors Hangout for mentioning the company in their podcast. Links to Advantis websites can be found at advantiscorp.com, rosin6.com, elixicure.com, and amstercan.com About Advantis CorporationAdvantis Corporation (ADVT) focuses on the development of innovative products that supply the medical, research, and pharmaceutical industries. The company additionally establishes partnerships with businesses that develop and sell proprietary pain management, and consumer products and services. Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward- looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act. For further information, contact: Media Relations Contact Name: Woo Kim, Director Organization: Advantis Corporation Phone: 949-354-3585 Address: 1048 Irvine Ave. #900 Newport Beach, CA 92660 E-mail: info@advantiscorp.com
March 04, 2019

Cardiff Lexington Corporation Reduces Debt

Page
Ft. Lauderdale, FL - (NewMediaWire) - March 04, 2019 - Cardiff Lexington Corporation (OTC:CDIX) announced today the retirement of eight convertible notes entered into by the Company between September 2016 and November 2018.“We have made significant inroads to reduce debt. Today’s announcement demonstrates our commitment to improve the Company’s balance sheet and strengthen our financial foundation,” stated Alex Cunningham, Cardiff Lexington’s CEO. “The elimination of several variable rate, floating price, convertible notes has strengthened our balance sheet and simplified our capital structure. We will continue working to restructure the Company for future growth.” As a result, the Company’s eight (8) convertible notes which had been currently convertible at variable prices reflecting a predetermined discount to market prices, have been retired and the Company has eliminated this indebtedness. About Cardiff Lexington Corporation: Cardiff Lexington is a public holding company, much like a cooperative, leveraging proven management in private companies that become subsidiaries. Our focus is not industry or geographic-specific, but rather proven management, market, and margin. Cardiff Lexington targets acquisitions of mature, high growth, niche companies. Cardiff Lexington's strategy identifies and empowers select income-producing middle market private businesses and commercial real estate properties. Cardiff Lexington provides these companies both 1) the enhanced ability to raise money for operations or expansion, and 2) an equity exit and liquidity strategy for the owner, heirs, and/or Investors. For investors, Cardiff Lexington provides a diversified lower risk to protect and safely enhance their investment by continually adding assets and holdings. Cardiff Lexington is led by strong and talented team of executives and advisors providing expert acquisition, market guidance and added value for subsidiaries and investors. FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.Investor Relations 844-628-2100 ext. 705 investorrelations@cardifflexington.com
March 04, 2019

NexTech CEO, Evan Gappelberg, to Appear on Cheddar TV to Showcase AR for eCommerce Technology

Page
Toronto, Ontario - (NewMediaWire) - March 04, 2019 - NexTech AR Solutions (the “Company” or “NexTech”) (CSE: NTAR) (OTC: NEXCF)(FSE:N29) today announced that its CEO, Evan Gappelberg, is scheduled to appear live on Cheddar TV this afternoon at 1:10pm ET.Gappelberg will be showcasing NexTech’s AR for eCommerce technology, including the new ‘Try-It-On’ functionality and updated user experience, as well as sharing his predictions for the future of augmented reality and the eCommerce industry.Viewers can tune into the Cheddar news segment by live streaming on Cheddar’s website or downloading the Cheddar app in the Apple Store or Google Play.Cheddar is the leading post-cable, live-streaming video news network focused on covering the most innovative executives, founders, products, and technologies transforming our lives and economy.About NexTech AR Solutions Corp.NexTech is bringing augmented reality (AR) to the Cannabis industry and to the masses by creating an AR ecosystem featuring eCommerce solutions for websites, AR learning and education tools, and AR live streaming for events. With just a few lines of embed code, the Company’s patent-pending technology can integrate into existing eCommerce platforms, providing retailers with a highly scalable platform that increases customer engagement and sales. To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.On behalf of the Board of NexTech AR Solutions Corp.“Evan Gappelberg”CEO and DirectorThe CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.For further information, please contact: Evan Gappelberg Chief Executive Officer info@nextechar.com Media contact: Erin Hadden FischTank Marketing and PR ehadden@fischtankpr.com
March 04, 2019

Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog

Page
Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the RetinaLONG BEACH, CA - (NewMediaWire) - March 04, 2019 - Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with Noramco, Inc. (Noramco) for the manufacturing and scale-up of Nemus’ proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi. Noramco is a recognized, global producer and provider of controlled substances, including cannabinoids, to the pharmaceutical industry.Unlike a prodrug which must be metabolized into the active drug form, an analog has its own intrinsic pharmaceutical activity. Early animal studies of the analog, cannabidiol-valine-hemisuccinate (CBDVHS), have demonstrated improved bioavailability when compared to CBD, based on chemical modifications to the molecule utilizing amide ester bioengineering developed at the University of Mississippi. These attributes, including cannabinoid-based neuroprotection, could be especially important in ocular diseases, where penetrance into the posterior chamber of the eye could potentially expand therapeutic options into diseases of the retina, like macular degeneration and diabetic retinopathy. “Noramco is looking forward to working with Nemus and helping to advance the unique analog CBDVHS through process development and cGMP manufacturing,” commented Bill Grubb, Chief Innovation Officer and Vice-President of Global Business Development. “Contracting with Noramco signals the launch of the CBD-analog program to advance this candidate molecule into pre-clinical development, with a near-term goal to conduct clinical trials to address diseases of the eye,” noted Brian Murphy, M.D., CEO-CMO of Nemus. “Noramco has particular expertise in working with cannabidiol and CBD-derivatives, making them a strategic part of the CBDVHS development plan.” About NoramcoNoramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. The company offers cannabinoids and other APIs for use in abuse deterrence, attention deficit disorder, pain management, and addiction management. Established in 1979, Noramco maintains production and R and Neuhausen, Switzerland; and accesses agricultural operations in Tasmania through an affiliate, Tasmanian Alkaloids. Additional information about Noramco can be obtained by visiting Noramco’s web site at www.Noramco.comAbout Nemus Bioscience, Inc.Nemus is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary synthetic compounds, alone or in combination with corporate partners. Nemus is part of the Emerald Health group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.For more information, visit www.nemusbioscience.comFORWARD LOOKING STATEMENTS This press release contains forward-looking statements, including statements regarding our product development, business strategy, product milestones, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations ...
March 04, 2019

Ubiquitech Reports 2018 Gross Annual Revenues of $3,760,099

Page
Denver, CO - (NewMediaWire) - March 04, 2019 - Ubiquitech Software Corp. (OTC: UBQU), through its operating subsidiary HempLifeToday.com, today announced its fiscal year end 2018 financial results. Revenues for the year were $3,760,099, and the company had net income of $5,275 for the year ending November 30, 2018.CEO, James Ballas, said: “We are extremely happy to report company results for the fiscal year end 2018. As CEO, I am well aware that results have leveled off over the last few quarters and this is due to the fact that the company continued to invest heavily in growth strategies while regulatory and industry conditions remained challenging. The company will continue to adjust and invest throughout the first half of the current fiscal year. The CannazALL brand recognition initiatives currently being developed will continue to solidify our foothold in the growing CBD marketplace, and we expect improved growth now that favorable legislation has been enacted. With our investment in the company we look forward to improving and expanding our customer support, increasing the speed in which customers receive products, improving our customer online experience, adding new CannazALL CBD products, increasing our advertising budgets and exploring new ad platforms, and announcing phase two of our extremely popular Ambassador Program. The entire staff at HempLife Today is working hard and we firmly believe that we are on the right track to achieve all of our stated goals for the company. Please bear with us as we continue to build the company and we will have lots of exciting news to come, including updates on our name and symbol change which we know you all are waiting for.”About Ubiquitech Software CorpUbiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, DirectResponse (DRTV) Television, Radio, Internet Content, and traditional marketing to drive traffic to the new and emerging multi-billion dollar industries like its subsidiaries HempLifeToday™ and CryptoBuy.comAbout HempLife Today™HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Concentrated Oils, GelCaps, Skin Salve, e-liquid, and CannazALL Pets™ CBD products all offered @ www.HempLifeToday.comAbout CryptoBuyCryptoBuy.com focuses on the burgeoning new world of Crypto Currencies and is created to be a service to persons interested in tracking and trading the many existing and future Crypto Currencies worldwide.This press release contains forward-looking statements. Words such as "expects", "intends'', "believes'', and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the after the date of this release.Contact / Investor relations IR@UbiquitechSoftware.com
March 04, 2019

Gopher Completes Initial Testing of MESH Radio System

Page
San Diego, CA - (NewMediaWire) - March 04, 2019 - Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher”), a company specializing in the development of Internet of Things (IoT) and Artificial Intelligence enabled networking and tracking technologies, including its GopherInsight global mesh network technology platform for both mobile and fixed solutions, today announced it has completed its initial testing of its MESH Radio system with satisfactory results.These initial tests were conducted in order to evaluate the functionality and performance of Gophers MESH radio system and included an evaluation of radio spectrum as defined by the Company’s Design Verification Testing (DVT) protocol. Test results included… "This is an exciting moment for us as we see our MESH system realizing our plan under rigorous testing conditions, " stated Danny Rittman, Gopher CTO. "OTA testing is the first stage of architecture radio testing. With this initial stage complete, we now shift our focus towards improving the system’s results primarily through firmware and antennas. Additionally, in a few weeks, testing of power consumption will also be conducted in order to ensure substantial battery life."About Gopher Protocol Inc.Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher”) (http://gopherprotocol.com/) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. Gopher has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. Gopher’s system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. Gopher envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.https://www.avant-ai.netForward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.Contact: Dr. Danny Rittman, CTO Gopher Protocol Inc. Media: press@gopherprotocol.com
March 04, 2019

New scientific statement on blood pressure measurement in people

Page
Statement highlights: Oscillometric devices, which use an electronic pressure sensor within the blood pressure cuff, can reduce human error and the risk to the environment from older devices which use mercury. Patients who measure their blood pressure at home should use a device with an upper arm cuff that has been checked for accuracy by a healthcare provider. Embargoed 4 a.m. CT / 5 a.m. ET Monday, March 4, 2019 (NewMediaWire) - March 04, 2019 - DALLAS - The accurate measurement of blood pressure is essential for the diagnosis and management of hypertension, a major risk factor for heart disease and stroke, according to an updated American Heart Association scientific statement on blood pressure measurement in humans, published in the American Heart Association journal Hypertension. The statement, which updates a previous statement on the topic published in 2005, provides an overview of what is currently known about blood pressure measurement. and supports recommendations in the 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure The auscultatory method – where a healthcare provider uses a blood pressure cuff, a stethoscope and a mercury sphygmomanometer (device that measures blood pressure) – has been the gold standard for office blood pressure measurement for several decades. The mercury sphygmomanometer has a simple design and is not subject to substantial variation across models made by different manufacturers. However, mercury devices are no longer being used due to environmental concerns about mercury. “Many oscillometric devices, which use an electronic pressure sensor within the blood pressure cuff, have been validated (checked for accuracy) which allow for accurate blood pressure measurement in the healthcare office settings while reducing human errors associated with the auscultatory approach,” said Paul Muntner, Ph.D., chair of the writing group for the scientific statement. “Additionally, newer automated oscillometric devices can obtain multiple measurements with the single push of a button, which can be averaged to better estimate blood pressure,” said Muntner, who is also a professor at the University of Alabama at Birmingham. The statement also summarizes current knowledge about ambulatory blood pressure monitoring, which is done when a patient wears a device which measures their blood pressure throughout the day to identify white coat hypertension and masked hypertension. Substantial data have been published since the last Scientific Statement in 2005 showing the importance of measuring blood pressure outside of the clinic setting. White coat hypertension, when blood pressure is raised in the healthcare office setting but not at other times and masked hypertension where blood pressure is normal in the healthcare office setting but raised at other times. As detailed in the Scientific Statement, patients with white coat hypertension may not have an increased risk for cardiovascular disease and may not benefit from initiating antihypertensive medication. In contrast, patients with masked hypertension have a substantial increased risk for cardiovascular disease. The 2017 hypertension guideline also recommends conducting ambulatory blood pressure monitoring to screen for white coat hypertension and masked hypertension in clinical practice. The American Heart Association continues to recommend patients measure their blood pressure at home using a blood pressure device with an upper arm cuff that has been checked for accuracy by a healthcare provider. Co-authors are Daichi Shimbo, M.D., Vice-Chair; Robert M. Carey, M.D.; Jeanne B. Charleston, Ph.D.; Trudy Gaillard, Ph.D.; Sanjay Misra, M.D; Martin G. Myers, M.D.; Gbenga Ogedegbe, M.D.; Joseph E. Schwartz, Ph.D.; Raymond R. Townsend, M.D.; Elaine M. Urbina, M.D., M.S.; Anthony J. Viera, M.D., M.P.H.; William B. White, M.D.; and Jackson T. Wright, Jr, M.D., Ph.D. Additional Resources: Multimedia available for download on the right column of the release ...
March 04, 2019

Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape

Page
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
March 01, 2019

For The Earth Corporation Provides Acquisition Update

Page
Phoenix, AZ - (NewMediaWire) - March 01, 2019 - Phoenix, AZ - (NewMediaWire) - March 01, 2019 - For The Earth Corporation (the “Company”) (OTC: FTEG) is excited to provide acquisition update.Acquisitions Update:“I would like to comment on the latest announcement regarding For The Earth’s acquisition of the Chow brand. As we all know, when one company acquires another (or when a company is only acquiring another companies brand name), there is always apprehension from both parties. After the agreement was signed, I decided it wasn’t the right fit for FTEG. The number of vending machines that Vliso’s management team wanted to launch {in 2019} was extremely aggressive. This in turn would not allow for other acquisitions, development of new products, and marketing campaigns. It would not support FTEG in creating strong revenues and would have forced our focus from long term shareholder value. “We will concentrate efforts on the launch of our Las Vegas vending machines, kiosks and inline retail store,” said Nelson Grist, President and CEO of For The Earth Corporation. “Vlsio is a great startup company, with great a management team who are young and highly skilled, I wish them well!”If you have any questions, please send an email to the FTEG Investment Team.infofteg@gmail.comAbout For The Earth CorporationFor The Earth Corporation is an emerging integrated CBD producer and retailer in the United States. The Company is in the process of establishing a vertical framework that will extend from cultivation to extraction and production to a strategic retail footprint. that includes multiple locations, featuring mall kiosks, vending machines, e-commerce, and full store locations serving both the human and pet CBD markets. Two mall leases have been signed recently in Las Vegas, with another vending machine location secured in New York City. The Company plans to expand its New York vending machine penetration by the end of 2019. In addition, the Company has begun early-stage work to establish a state-of-the-art CBD extraction and production facility in Eugene, OR.Forward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See For The Earth’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.Safe Harbor StatementThis release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Press & Media Inquiries: EHC Branding Agency Info@EHCBrandingAgency.com (626) MJ-BRAND For The Earth Corporation 20 E Thomas Rd. Phoenix, AZ 85012 USA Contact: Nelson Grist Telephone: 602 502-0602 Email: infofteg@gmail.com
Unique Foods Corp (UPZS) Announces Removal of $495k Debt
March 01, 2019

Unique Foods Corp (UPZS) Announces Removal of $495k Debt

Page
Pittsburgh PA - (NewMediaWire) - March 1, 2019 - Unique Foods Corporation (OTCPK: UPZS) announces the removal of a $495,000 debt that has been carried on the corporate books for the past sixteen quarters. This debt has been deemed by corporate counsel and accountants to not be the responsibility of Unique Foods Corp and should be removed from the past and omitted from future filings.This “Note 5” section will be removed from all past filings along with $495,000 debt from the balance sheet “Note Payable to a Related Party Individual”. Over the next few months all of the previous filings that included this debt will be amended and when the 2018 year end financials are posted the $495k will be omitted.Note 5 – Note Payable to a Related Party IndividualPursuant to the Company’s variable interest entity relationship with a California based restaurant, the Company incurred a promissory note in the amount of $495,000. The amount payable to the individual, related through the variable interest entity relationship as the mother of the managing member of Credo Ventures, LLC who loaned the monies to Credo Ventures, LLC, at September 30, 2018 is $495,000.The promissory note bears interest of 10% per annum, has equal monthly payments payable of $10,517 over sixty months maturing on October 17, 2020 and the restaurant equipment is the collateral.James C. Vowler, President & CEO of Unique Foods Corp., stated, “When the debt was occurred it was paid directly to Credo Ventures and as a result, Unique Foods Corp should not have registered the debt on our books. The removal of this debt is certainly a positive step for the company and combined with all of the other exciting achievements going on with Unique 2019 is starting off great.”About Unique Foods Corporation:Unique Foods Corp. partnered with Jack Brewer (Unique Foods Brand Ambassador) & Brewer Media & Entertainment Group in October of 2017. Brewer Media Group was brought on to help build all aspects of the many Unique brands. With a primary focus on the increase of online and retail sales, social media presence and overall content, public persona and awareness, acquire acquisition opportunities and much more. The company has three wholly owned subsidiaries Jose Madrid Salsa, Unique Tap House and PopsyCakes and a Licensing agreement with Christopher Street Products.The Unique Tap House 39809 Avenida Acacias, Murrieta, CA 92563, To Book your office or birthday party, special event, group reservations or to order food call (951) 445-4769.Twitter: @ChristopherS_T_@uniquefoodscorp@MadridSalsa@PopsyCakes@UniquePizzaTapHInstagram: instagram.com/unique_foods_corpWebsites:Unique Foods Corp.: http://www.UniqueFoods.coJose Madrid Salsa: http://www.JoseMadridSalsa.comPopsyCakes: http://www.PopsyCakes.comChristopher Street Products: http://www.ChristopherStreet.NYCSafe Harbor Act: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward- looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions. There are no financials in this press release so this is not needed and undermines the release.For Unique Foods Corp. Investor Relations contact Complete Advisory Partners Phone: (586) 228- 2290 Fax: (586) 228-6920 capinc@comcast.net http:/www.capinc.net
1 2 3230 231 232 233 234527
Showing 23112320 of 5261 Items